intravenous glutathione randomized controlled trial parkinson's disease Phase 1/2a clinical of hESC-derived dopamine progenitors in disease: Cell Novel targeted therapies for Parkinson's
Description
References Guangyan, Y
Cells were treated in 100 L of media
[DOI] [PMC free article] [PubMed] [Google Scholar] 7.Jing J., Peng Y., Fan W., Han S., Peng Q., Xue C., Qin X., Liu Y., Ding Z
As a next step, the reader measured continuously for 6 min the fluorescence intensity at 410 and 470 nm (510 nm of emission) of each well to determine the cytoplasmic pH before treatment
While this is a conspicuous advantage of 4-DPS, the longer wavelength maximum for TNB, over the pyridone product of 4-DPS, makes DTNB more suitable for the quantification of thiols in solutions that strongly absorb in the near UV
